Argenx
About Argenx
Argenx is a clinical-stage biotechnology company developing a pipeline of differentiated antibody-based therapies for autoimmune diseases and cancer.
Leadership Team
Leadership as listed on argenx.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
Karen Massey
Products & Services
Products and services as listed on argenx.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.
VYVGART (efgartigimod)
Therapy designed to block FcRn, marketed for generalized myasthenia gravis.
Source: argenx.comEmpasiprubart
Investigational therapy for severe IgM-driven autoimmune diseases.
Source: argenx.comPipeline & Regulatory Record
What public registers list for Argenx: clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 20 Nov 2026.
Clinical trials 40 in our ClinicalTrials.gov registers · 6 in the EU register
Showing 10 of 40, trials with Irish sites first. The full lists are on the sponsor pages below.
All trials by sponsor name 1 registry name
Drugs in these trials 6 compounds
EU trials register (CTIS) 6 authorised or ongoing
- An Open-Label, Single-Arm, Phase 1b Study to Evaluate the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy2026-525171-20-00 · Phase I · Authorised
- A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy2025-520805-10-00 · Phase III · Ongoing
- A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren’s Disease-Associated Sensorimotor or Sensory Polyneuropathy2026-526218-10-00 · Phase II · Ongoing
- Master Protocol Full Title- A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 2 to Master Protocol ARGX-999-2-MG-2000 – an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis2025-522939-33-00 · Phase II · Ongoing
- A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ARGX-121 SC in Adult Participants With Primary IgA Nephropathy2026-525638-43-00 · Phase II · Ongoing
- A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy2024-520097-36-00 · Phase III · Ongoing
NICE technology appraisals 1 of its medicines · 1 current
- Efgartigimod for treating antibody-positive generalised myasthenia gravisNICE TA1069 · Not recommended · 4 Jun 2025
Appraisals of medicines sold under a brand this company holds in EMA or FDA records, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Group (Argenx): founded 2008, headquarters Ghent, website argenx.com. Wikidata Q63152908 · Wikipedia. From Wikidata (CC0), matched by the group's Legal Entity Identifier.
How this is matched: register records are linked to this page by the organisation name they carry, here argenx; Argenx. Spot a wrong match? Tell us.
Financials & Irish Entities
From the annual reports argenx SE files with the US Securities and Exchange Commission (20-F, IFRS), in USD as reported. Latest financial year: to Dec 2025.
| Year to | Revenue | R&D | R&D % | Net income | Filing |
|---|---|---|---|---|---|
| Dec 2025 | $4.15bn | $1.36bn | 32.9% | $1.29bn | 20-F 2026 |
| Dec 2024 | $2.19bn | $983m | 45.0% | $833m | 20-F 2026 |
| Dec 2023 | $1.19bn | $859m | 72.2% | −$295m | 20-F 2026 |
| Dec 2022 | $401m | $663m | 165.5% | −$710m | 20-F 2025 |
| Dec 2021 | $497m | $581m | 116.7% | −$408m | 20-F 2024 |
Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.